Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma
Authors:
Top Cited Papers
- 1 July 2019
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 17 (7) , 840-847
Abstract
Background: Although venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs), no validated clinical model predicts VTE in this population. This study aimed to derive and validate a new risk assessment model (RAM) for IMiD-associated VTE. Methods: Patients with newly diagnosed MM receiving IMiDs were selected from the SEER-Medicare database (n=2,397) to derive a RAM and then data from the Veterans Health Administration database (n=1,251) were used to externally validate the model. A multivariable cause-specific Cox regression model was used for model development. Results: The final RAM, named the “SAVED” score, included 5 clinical variables: prior surgery, Asian race, VTE history, age ≥80 years, and dexamethasone dose. The model stratified approximately 30% of patients in both the derivation and the validation cohorts as high-risk. Hazard ratios (HRs) were 1.85 (P<.01) and 1.98 (P<.01) for high- versus low-risk groups in the derivation and validation cohorts, respectively. In contrast, the method of stratification recommended in the current NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease had HRs of 1.21 (P=.17) and 1.41 (P=.07) for the corresponding risk groups in the 2 datasets. Conclusions: The SAVED score outperformed the current NCCN Guidelines in risk-stratification of patients with MM receiving IMiD therapy. This clinical model can help inform providers and patients of VTE risk before IMiD initiation and provides a simplified clinical backbone for further prognostic biomarker development in this population.Keywords
This publication has 25 references indexed in Scilit:
- External validation of a Cox prognostic model: principles and methodsBMC Medical Research Methodology, 2013
- Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United StatesThrombosis Research, 2010
- The Performance of Risk Prediction ModelsBiometrical Journal, 2008
- Development and validation of a predictive model for chemotherapy-associated thrombosisBlood, 2008
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the CensusThe American Journal of Medicine, 2004
- Incidence of symptomatic venous thromboembolism after different elective or urgent surgical proceduresThrombosis and Haemostasis, 2003
- Overview of the SEER-Medicare DataMedical Care, 2002
- An introduction to the Barell body region by nature of injury diagnosis matrixInjury Prevention, 2002